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Rhabdomyosarcoma (RMS) in children occurs as two
major histological subtypes, embryonal (ERMS) and
alveolar (ARMS). ERMS is associated with an 11p15.5
loss of heterozygosity (LOH) and may be confused
with nonmyogenic, non-RMS soft tissue sarcomas.
ARMS expresses the product of a genomic transloca-
tion that fuses FOXO1 (FKHR) with either PAX3 or
PAX7 (P-F); however, at least 25% of cases lack these
translocations. Here, we describe a genomic-based
classification scheme that is derived from the com-
bined gene expression profiling and LOH analysis of
160 cases of RMS and non-RMS soft tissue sarcomas
that is at variance with conventional histopathologi-
cal schemes. We found that gene expression profiles
and patterns of LOH of ARMS cases lacking P-F trans-
locations are indistinguishable from conventional
ERMS cases. A subset of tumors that has been histolog-
ically classified as RMS lack myogenic gene expression.
However, classification based on gene expression is
possible using as few as five genes with an estimated
error rate of less than 5%. Using immunohistochemis-
try, we characterized two markers, HMGA2 and
TFAP2ß, which facilitate the differential diagnoses of
ERMS and P-F RMS, respectively, using clinical material.
These objectively derived molecular classes are based
solely on genomic analysis at the time of diagnosis and
are highly reproducible. Adoption of these molecular
criteria may offer a more clinically relevant diagnostic
scheme, thus potentially improving patient manage-
ment and therapeutic RMS outcomes. (Am J Pathol 2009,
174:550–564; DOI: 10.2353/ajpath.2009.080631)
Rhabdomyosarcoma (RMS) defines a group of histolog-
ically and genetically heterogeneous sarcomas that are
the single most common soft tissue sarcomas affecting
children and young adults. Two major forms of the dis-
ease are described,1–5 conventionally termed embryonal
RMS (ERMS) and alveolar RMS (ARMS), reflecting mor-
phological similarities to fetal muscle or pulmonary alve-
oli, respectively. These distinctions are clinically relevant
because the embryonal form typically shows less aggres-
sive clinical behavior and a better prognosis and mor-
phological embryonal variants such as spindle/botryoid
tumors5–7 are highly curable. When clinical stage and
other variables are taken into account, survival rates
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range from 20% for patients with metastatic alveolar his-
tology tumors to more than 95% for some localized forms
of ERMS.8,9
Recurrent chromosomal translocations10,11 that result
in the expression of the chimeric transcription factors,
PAX3-FOXO1 or PAX7-FOXO1 (henceforth, P-F or PAX-
FKHR), and that can be detected by molecular genetic
techniques, are found exclusively in ARMS. Initially this
was thought to provide an objective basis for distinguish-
ing the two major forms of the disease.10 However, anal-
ysis of a large series of cases consistently fails to show an
absolute association of P-F translocations with ARMS; at
least 25% of these tumors possess classic alveolar his-
tology but lack a translocation.12,13 The most recent work
from the Children’s Oncology Group (COG) cites a figure
as high as 45% for ARMS histology cases lacking known
P-F fusions.14 In contrast, ERMS do not demonstrate
recurrent chromosomal translocations (ie, P-F-negative).
Instead, they show greater genomic instability (mani-
fested as highly variable karyotypes) and recurring allelic
imbalances such as loss of heterozygosity (LOH) at chro-
mosome 11p15.5.15,16
RMS is defined as demonstrating at least minimal ev-
idence of rhabdomyogenesis, or skeletal muscle differ-
entiation. However, in a large proportion of cases, mor-
phological evidence of myogenesis is limited to a small
percentage of tumor cells or may be extremely difficult to
detect. The use of antibodies for immunohistochemical
(IHC) detection of myogenesis-associated proteins such
as desmin, myogenin (MYOG), and MyoD (MYOD1) have
aided the diagnostic workup of such cases,17,18 and
when combined myogenin and MyoD have 97% sensi-
tivity to detect RMS.19,20 The identification of muscle
related differentiation is key and clinically relevant be-
cause some RMS cases can be virtually indistinguishable
from the group of so-called undifferentiated or nonrhab-
domyosarcoma soft-tissue sarcomas (UDS/NRSTS). The
latter lack any morphological or ultrastructural evidence of
myogenesis and have a poor outcome compared with
RMS.21,22 Formerly, UDS/NRSTS was considered a diagno-
sis of exclusion but on current COG protocols (eg, D9902)
these patients are not eligible for RMS clinical trials.
The Intergroup Rhabdomyosarcoma Study Group
(IRSG) was formed as a multi-institutional cooperative
effort to better understand the biology of RMS and to
improve the outcome of this disease.7 Such cooperative
efforts have resulted in dramatic improvement of RMS
patient overall survival from 25% before the first IRSG-I
protocol to 71% on IRSG-IV.9,23,24 The recognition that
patient outcome is highly variable and dependent on
numerous clinicopathological risk factors resulted in the
development of a risk-based algorithm for treatment as-
signment, which combines a histological classification
scheme with presurgical stage and postsurgical clinical
group. A cornerstone of this risk-based assignment is the
histological diagnosis, criteria for which were developed
throughout several decades by numerous investigators
and culminating in the International Classification of
Rhabdomyosarcoma (ICR).3,25 ICR criteria, based mainly
on the morphological and cytological examination of he-
matoxylin and eosin-stained histology sections, resulted
in remarkable improvements in the reproducibility of di-
agnosis and provided a platform for survival models that
are predictive of patient outcome.1,3 However, despite ex-
haustive efforts to establish consensus for these diagnostic
criteria, as many as a third of patients could be incorrectly
assigned to treatment protocols because of inconsistency
and uncertainty as determined by institutional pathology
diagnosis—and is the primary reason for mandatory central
pathology review process at the COG.19
Genomic analysis of human tumor specimens is hav-
ing a significant impact on the field of tumor pathol-
ogy,25,26 redefining tumor classes based on molecular
features27,28 and identifying new subclasses previously
unrecognized by conventional histology or cytogenet-
ics.29 We therefore sought to determine whether a new
molecular-based classification scheme derived from
analysis of gene expression profiles and whole-genome
patterns of LOH might be better suited to define a heter-
ogeneous disease such as RMS than conventional histo-
logical methods. Analysis was performed on initial diag-
nostic biopsy specimens from 160 cases of RMS drawn
primarily from (IRSG)-IV and (IRSG)-V RMS studies con-
ducted by the COG.8,9,21 These samples were analyzed
using Affymetrix (Santa Clara, CA) 22,000 gene U133A
expression arrays and 10,000 SNP mapping arrays, and
results were validated by reverse transcriptase-polymer-
ase chain reaction (RT-PCR) and IHC of primary tumor
material. Based on our studies we have identified classes
of RMS that differ markedly from those of conventional
classification schemes including the ICR. These molec-
ularly defined classes are highly reproducible and can be
objectively defined, thus providing several advantages
over those of current histopathological classification
schemes. Moreover, molecular classification imparts
prognostically relevant information that may be useful in
optimizing risk-adapted therapy.
Materials and Methods
Tumor Specimens
Tumor specimens were obtained from the Intergroup
Rhabdomyosarcoma Study Group/Pediatric Cooperative
Human Tissue Network (Columbus, OH) and Children’s
Hospital Los Angeles institutional tumor banks from 160
patients that were enrolled in IRSG IV and V COG clinical
trials. Frozen tumor samples were sectioned and repre-
sentative sections were examined. Only samples with
tumor cell content of at least 80% were included for
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analysis. Clinical covariates were obtained from the COG
Research Data Center (Arcadia, CA). For clinical charac-
teristics of the data set see Table 1 and Supplemental
Table S1 available at http://ajp.amjpathol.org for individ-
ual sample covariate data.
Histology and Molecular Diagnosis
Centrally reviewed (IRSG/Cooperative Human Tissue
Network) histological diagnoses were based on the Inter-
national Classification of Rhabdomyosarcoma criteria, in
accordance with IRSG protocols.3,19 Mixed alveolar/em-
bryonal tumors or tumors with any evidence of alveolar
histology, classical, or solid variant were classified as the
alveolar subtype (ARMS, n  70). Embryonal tumors
were all of classical histology, botryoid or spindle cell
variants (Table 1) or not-otherwise specified (ERMS, n 
78). Undifferentiated sarcomas or those sarcomas des-
ignated as other because of indeterminate/uncertain di-
agnosis (eg, non-RMS histology) but placed on RMS
treatment protocols were also evaluated (UDS/NRSTS,
n  12). RT-PCR using total RNA extracted from frozen
tissue was performed on all tumors with alveolar or mixed
alveolar/embryonal histology for detection of PAX3-FKHR
and PAX7-FKHR fusion transcripts.12 Additionally, 45 of
the ERMS and 8 of the UDS/NRSTS tumors were also
assayed for PAX-FKHR transcripts and all were found to
be P-F-negative in accordance with previously reported
data from IRSG-IV cases.12,13
RNA and DNA Isolation for Microarray
Expression and SNP Profiling
DNA and RNA were extracted from frozen tissues with
DNA STAT and RNA STAT-60, respectively (Tel-Test Inc.,
Friendswood, TX). RNA was purified with the RNeasy
protect kit (Qiagen, Valencia, CA) according to the man-
ufacturer’s instructions. Biotin-labeled cRNA was pre-
pared from total RNA and hybridized to Affymetrix Gene-
Chip human U133A expression arrays performed according
to the manufacturer’s instructions (Affymetrix). Genomic
DNA was digested with XbaI, PCR amplified, and hybrid-
ized to Affymetrix GeneChip 10K mapping arrays per-
formed according to the manufacturer’s instructions
(Affymetrix).
Analysis of Gene Expression
All data management and analyses were conducted us-
ing the Genetrix suite of tools for microarray analysis
(Epicenter Software, Pasadena, CA). Estimates of relative
mRNA abundances for each of the 22,215 probe sets
on the Affymetrix U133A expression microarray were
derived using the ProbeProfiler algorithm (Corimbia,
Berkeley, CA), which weights individual probes in each
probe set according to a principal components
model.30 Probe set filtering was used to remove genes
whose SD was less than 40 Affymetrix average differ-
ence intensity units across all of the samples reducing
the number of useable probe sets to 11,694 (hence-
forth, genes).31 Probe set average difference intensity
values were truncated at 1 and log transformed. The
complete tumor microarray data set can be found on
the National Cancer Institute Cancer Array Database at
https://array.nci.nih.gov/caarray/project/trich-00099.
k-Means Clustering
Semisupervised clustering was performed using a
k-means algorithm. Because the k-means method con-
verges to a local minimum, with the final clusters being
dependent on the starting position of the cluster cen-
troids, a metaclustering approach was used in which the
clustering was repeated 2000 times and the cluster mem-
bership information from each run was aggregated. For
each metaclustering run, i) the genes used for classifica-
tion were independently selected based on the signifi-
cance level for each gene in a Kruskal-Wallis H test of
homogeneity of the expression means values in each of
the three ICR histological groups, ii) the initial positions
of the k centroid means were randomly selected, iii) a
Table 1. Clinical Characteristics of Gene Expression
Microarray Data Set
No. %
Histology
Alveolar 66 41.3
Mixed alveolar/embryonal 4 2.5
Embryonal 69 43.1
Botryoid 3 1.9
Spindle 6 3.8
Undifferentiated or NRSTS* 12 7.5
Clinical groups
IA & IB 32 20.0
IIA & IIB 13 8.1
III 44 27.5
IV 26 16.3
Unknown 45 28.1
Alive/Dead
Alive 105 65.6
Dead 53 33.1
Unknown 2 1.3
Sex
Male 98 61.3
Female 52 32.5
Unknown 10 6.3
Primary site
Orbit 5 3.1
Head/Neck 12 7.5
Paramenigeal 22 13.8
Bladder/prostate 13 8.1
Genitourinary Other† 28 17.5
Extremity 39 24.4
Other 34 21.3
Unknown 7 4.4
Age groups
1 year 7 4.4
1–4 years 50 31.3
5–9 years 59 36.9
10–14 years 22 13.8
15 years 13 8.1
Unknown 9 5.6
*Review diagnosis of undifferentiated sarcoma or non-rhabdomyosarcoma
soft-tissue sarcoma.
†Non-bladder/prostate genitourinary tumors.
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random selection of n (test) samples were separated for
cross validation (leave-n-out sampling), where n was set
to 10% of the sample set, iv) the k-means algorithm was
applied to the remaining (training) samples, v) the mem-
bership of each of the n out-of-sample cases was based
on the closest training set centroid, vi) a pairwise similar-
ity matrix was cumulated across all metacluster runs,
based on the proportion of all runs in which both mem-
bers of the pair were present in the same test set that
placed both members in the same class, and vii) a mul-
tidimensional scaling analysis based on the final cumu-
lative similarity matrix was used to generate two-way
hierarchical clustering dendrogram. Probe set selection
criteria for Kruskal-Wallis H test used a false discovery
correction with a P value set to 0.00001 to provide an
estimated false discovery rate of 0.1%. Cluster centroids
discovery for P-F RMS tumors was done as described
above except a t-test was used to select for differentially
expressed genes between PAX3-FKHR and PAX7-FKHR
ARMS. The multidimensional scaling analysis showing
the relative proximities of each sample based on the final
cumulative similarity matrix of this first metaclustering
round can be seen in Supplemental Figure S1A available
at http://ajp.amjpathol.org. Two clusters of P-F RMS are
apparent, the colored circles denote the new tumor
classes that were used to select for differentially ex-
pressed genes in a second round of metaclustering. For
fusion-negative tumors the same procedure was applied
except using Kruskal-Wallis H test to initially select for
genes differentially expressed between spindle/botryoid,
embryonal, fusion-negative alveolar, and UDS/NRSTS tu-
mor groups. Clusters identified by this round of meta-
clustering were used to select for genes and derive the
clustering in a second round of metaclustering. Sam-
ples and genes were optimally ordered by complete-
linkage hierarchical clustering using Pearson’s corre-
lation metrics.
Nearest Shrunken Centroids
The nearest shrunken centroids algorithm, a derivative of
SAM (significance analysis of microarrays), developed
by Tibshirani and colleagues,32 and implemented within
Genetrix, was evaluated as a classification tool by calcu-
lation of the centroids for each of the three major tumor
classes (P-F RMS, F RMS, and UDS/NRSTS) as deter-
mined by our semisupervised metaclustering analyses.
Our objective was to define a minimal discriminatory
gene signature for RMS tumors and to determine whether
the consensus molecular classes observed with analysis
of the expression patterns of hundreds of genes (ie, P-F
RMS, P-F-negative RMS, and UDS/NRSTS), are reliably
identified with a shrunken subset of less than 20 genes.
Such a minimal expression signature would be more
suited than whole-genome arrays for routine clinical prac-
tice (eg, through the use of quantitative RT-PCR or other
low-density multiplex assays). Samples evaluated for this
analysis consisted of the 55 P-F-positive ARMS histology
tumors, 93 P-F-negative tumors (embryonal, spindle, bot-
ryoid, and alveolar) and 12 UDS/NRSTS histology tumors
(undifferentiated or other) (Figure 1). This combines the
accepted or consensus molecular genetic classifiers (ie,
P-F-positive or -negative) with the ICR histological clas-
sification scheme, and permits closer comparison of a
putative expression-based scheme to a purely histologi-
cal classification scheme. Classes were based on a
training set of samples and allocation of members of a
test set to the nearest centroid. The training and test
sets were created through a leave-n-out cross valida-
tion procedure (with n  16). The initial gene set for
classification was the 609 genes that were selected in
the all metaclustering analyses, and the centroids were
shrunken using a  value of   1.9. This analysis
identified five genes that were used to generate cen-
troids that predicted sample class probabilities with a
cross-validated error rate of 5%.
SNP Analysis
Single nucleotide polymorphism analysis for LOH deter-
mination was performed on Affymetrix 10K human SNP
Figure 1. Semi-supervised expression profiling of RMS and NRSTS tumors.
The Kruskal-Wallis H test was used to identify 485 differentially expressed
genes (used in at least 50% of the metaclustering rounds) between three main
ICR histological groups (ARMS, ERMS, and NRSTS) throughout 2000 rounds
of reiterative cross-validated metaclustering. A: Dendrogram derived from
Pearson’s correlation complete linkage hierarchical clustering of 160 tumor
samples, depicts two main branches that discriminate P-F RMS and all other
P-F-negative tumors. The colored legend indicates tumor histology (review
diagnosis) and PAX-FKHR (PAX-FOXO1) fusion status (ARMS only). B: Ex-
pression matrix depicting the expression patterns of two main gene clusters
of 363 and 122 genes differentially expressed between P-F RMS and P-F-
negative tumors (ie, two main branches of dendrogram in A). The expression
of each gene in each sample was normalized in the pseudo-colored heatmap
by the number of standard deviations above (red) and below (blue) the
median expression value (black) across all samples.
Microarray Analysis of Rhabdomyosarcoma 553
AJP February 2009, Vol. 174, No. 2
chips analyzed using the SNP analysis module of the
Genetrix Software package. Regions with LOH were de-
termined by statistical comparison to a pooled normal
DNA SNP reference profile available from Affymetrix and
based on observation of genomic stretches with an ex-
cess of homozygotic SNPs (relative to the expected fre-
quency, derived from SNP reference population allele
frequencies). Fractional allelic loss, a measure of ge-
nome-wide allelic imbalance was determined as de-
scribed previously.16
Survival Analysis
Comparison of survival times (censored overall and fail-
ure-free survival from the COG Biostatistics Center) was
performed using Kaplan-Meier survival plots and log-
rank tests of significance. Comparisons between tumor
classes and tests of association used Fisher’s exact or 2
tests where appropriate.
Functional Annotation of Gene Clusters
Functional annotation was performed using the Expres-
sion Analysis Systematic Explorer (EASE) software pack-
age for overrepresentation analysis of functional gene
categories and for multidatabase annotation of the differ-
entially expressed genes.31,34
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue microarrays
(TMAs) for ARMS and ERMS were obtained from the
Cooperative Human Tissue Network (Columbus, OH).
The ARMS TMA contained 96 tumor sections represent-
ing 32 individual ARMS tumors, 5 normal skeletal muscle,
and 5 ERMS tumors. The ERMS TMA contained 113
tumor sections comprised of material from 32 individual
ERMS, 5 normal skeletal muscle, and 5 ARMS tumors.
TMA were deparaffinized and rehydrated followed by
heat-induced epitope retrieval in a steamer (Black &
Decker, Towson, MD) using antigen Target Retrieval So-
lution (DAKO, Glostrup, Denmark) (for TFAP2) or 0.01%
pronase protease-induced epitope retrieval (HMGA2).
After incubation with normal serum, sections were incu-
bated with rabbit anti-TFAP2 (dilution 1:400; Santa Cruz
Biotechnology, Santa Cruz, CA) or rabbit anti-HMGA2
(dilution 1:500; Covance, Berkeley, CA), detected using
Vectastain Elite ABC kit and color was developed with
diaminobenzidine (Vector Laboratories, Burlingame, CA).
TMAs were counterstained with hematoxylin (for HMGA2)
or Methyl Green (for TFAP2). The control antibody, vi-
mentin (dilution, 1:40; Ventana, Tuscon, AZ), was used to
determine the integrity of tumor sections and array ele-
ments that were negative for vimentin were not scored.
Tumors cores were scored as positive if at least 10% of
tumor cells stained positively for the antigen in at least
two of the three TMA sections evaluated for each patient.
Slides were scored independently by two pathologists
(T.J.T. and D.E.S.). Sensitivity and specificity were deter-
mined as described previously.35
Results
Gene Expression Cluster Analysis of RMS
Tumors
To develop a molecular classification scheme for RMS
based on specific gene expression patterns of primary
diagnostic biopsies, we generated gene expression pro-
files on a cohort of 160 RMS and UDS/NRSTS tumors
(Table 1). Although, the proportion of histological variants
in this data set is reasonably representative of their inci-
dence as reported in IRSG clinical trials, we enriched the
numbers of cases with alveolar histology to include more
translocation-negative ARMS tumors for analysis.19 We
hypothesized, as has been reported previously on a
smaller cohort of cases,36–38 that histological RMS vari-
ants would be associated with distinct expression pro-
files, reflecting inherent biological and clinicopathologi-
cal differences. To determine the extent of the correlation
between the histological classification and sample gene
expression profiles, we initially used unsupervised hier-
archical clustering (without any supervised gene selec-
tion, using 11,694 probe sets that passed a variance
filter; see Materials and Methods). Using this method, we
did not observe any apparent homogeneous or robust
subgrouping of tumor clusters (eg, by histological
groups) (data not shown). We then used a novel semisu-
pervised learning approach, called metaclustering, to
identify both differentially expressed genes between the
major ICR histological groups (ie, ARMS, ERMS, and
UDS/NRSTS) and reproducible sample clusters (ie, sam-
ples with similar expression patterns). Metaclustering
was performed over numerous iterations with sample
membership in k-means cluster centroids determined by
the cumulative similarity of their gene expression profiles,
controlling for centroid false-discovery under leave-10%-
out sample cross-validation.39 After 2000 rounds of meta-
clustering, we identified 485 genes (Supplemental Table
S2 available at http://ajp.amjpathol.org), selected using
the Kruskal-Wallis H test that were differentially ex-
pressed between the three histological groups and used
in at least 50% of the cross-validated metaclustering
rounds. The genes and samples were then clustered
using complete-linkage hierarchical clustering and or-
dered using the Pearson’s correlation distance metric.
Hierarchical clustering analysis of the 160 tumors depicts
a dendrogram split into two main branches (Figure 1A).
Most of the tumors with ARMS histology and PAX-FKHR
expression cluster together on one branch of the dendro-
gram, whereas ERMS histology tumors including spindle
cell and botryoid variants comprised the second branch.
However, nearly 20% of tumors with alveolar histology
clustered with the ERMS tumors and only one of these
tumors expressed a PAX-FKHR fusion gene variant. In
addition, we observed a small subclade off of the main
ERMS tumor dendrogram branch that contained most of
the UDS/NRSTS cases, but this clade was also inter-
mixed with an equal proportion of ERMS tumors. In the
corresponding expression matrix presented in Figure 1B,
we observe two primary gene clusters including 363
genes with increased expression in PAX-FKHR (P-F RMS)
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and 122 genes with increased expression in P-F-negative
RMS tumors.
To better understand the functional significance of
these distinct tumor expression patterns, we used over-
representation analysis of Gene Ontology (GO) annota-
tions for the identification of biological themes (Supple-
mental Table S3 available at http://ajp.amjpathol.org)
overrepresented in the gene cluster associated with high
expression in P-F RMS were genes mapping to chromo-
some 6, specifically 6q and GO Biological Process neu-
rogenesis. In contrast, in the gene cluster highly ex-
pressed in P-F-negative tumors (alternatively, repressed
in P-F RMS), genes on chromosome 8, specifically 8q
were statistically overrepresented. Two main classes of
tumors are apparent and are tightly correlated to the
expression of PAX-FKHR fusion genes (ARMS only), or
lack thereof (P-F-negative RMS and UDS/NRSTS) in
these tumors. This expression signature is independent
of tumor histology because P-F-negative ARMS cases
cluster with tumors of embryonal and spindle/botryoid
histologies but not with alveolar morphology tumors that
express PAX-FKHR.
We next performed further metaclustering analyses
aimed at determining if additional classes of tumors (ie,
those not recognized by conventional histopathological
criteria), could be derived from the gene expression data.
For tumors that express PAX-FKHR fusions (P-F RMS), we
reasoned that molecular-based subclasses of these tu-
mors would reflect expression of either PAX3-FKHR or
PAX7-FKHR fusion variants. We implemented the meta-
clustering algorithm on 55 cases of P-F RMS, using a
paired t-test to select for genes differentially expressed
between PAX3-FKHR- and PAX7-FKHR-positive ARMS
tumors. A total of 199 genes differentially expressed be-
tween PAX3-FKHR- and PAX7-FKHR-positive tumors
were identified to participate in cluster centroid genera-
tion in at least 50% of the cross-validated metacluster
rounds (data not shown). A multidimensional scaling plot
generated from the cumulative test similarity matrix de-
picts two clearly defined clusters (Supplemental Figure
S1A available at http://ajp.amjpathol.org). These clusters
were not, however, strictly correlated to the type of PAX-
FKHR fusion variant expressed in these ARMS tumors. A
smaller cluster (n  17) contained most of the PAX7-
FKHR cases but also some PAX3-FKHR tumors, whereas
the larger cluster (n  38) comprised 90% of the PAX3-
FKHR-positive ARMS. A second metaclustering round
was initiated but this time we defined the two sample
clusters derived in the first metaclustering round as de
novo tumor classes to query for differentially expressed
genes in a similar manner in a second round of k-means
metaclustering. In Figure 2, a two-way hierarchical clus-
tering dendrogram (Figure 2A) and expression matrix
(Figure 2B) depict the clustering of the ARMS samples
and 222 genes (identified in at least 50% of the cross-
validated runs). Two distinct gene expression signatures
can be recognized (Supplemental Table S4 available at
http://ajp.amjpathol.org). The smaller PAX7-FKHR-like
cluster (n  16, P7F-like), comprised of 11 PAX7-FKHR
and 5 PAX3-FKHR tumors, display increased expression
of a cluster of 134 genes. The larger PAX3-FKHR-like
cluster (n  39, P3F-like) contained a small number of
PAX7-FKHR (n  5) but most of the PAX3-FKHR tumors
and had increased expression of a cluster of 88 genes.
Overrepresentation analysis showed biological and func-
tional distinction with the P7F-like gene cluster enriched
for genes localized to chromosome 13q arm whereas
P3F-like was enriched for genes localized to chromo-
some 4q (Supplemental Table S5 available at http://ajp.
amjpathol.org). This analysis supports the existence of
two subclasses of ARMS that are not absolutely corre-
lated to the fusion variant expressed, but rather reflect
distinct gene expression signatures for PAX3-FKHR-like
and PAX7-FKHR-like tumors, respectively.
A similar strategy was then implemented for all P-F-
negative RMS and UDS/NRSTS tumors (n  105). We
used the Kruskal-Wallis H test to query for differential
gene expression patterns among the four histological
categories assigned for these P-F-negative tumors (UDS/
NRSTS, ARMS, ERMS, and spindle/botryoid morphol-
Figure 2. Semi-supervised expression profiling of P-F RMS tumors. P-F-
expressing ARMS tumors (n 55) were subjected to two consecutive rounds
of cross-validated metaclustering. The results of the second round of meta-
clustering are presented in the hierarchical clustering dendrogram (A) and
expression matrix (B). Most PAX7-FKHR (purple dots) ARMS co-cluster on
the left branch of the dendrogram with five PAX3-FKHR ARMS. The left
branch is comprised of mainly PAX3-FKHR ARMS (red dots) but also includes
five PAX7-FKHR ARMS (30% of this group). The expression matrix depicts
the 134-gene P7F-like expression signature, with mean expression for the
P7F-like tumors (purple bar) 2.8-fold greater than P3F-like tumors (P 
0.0001) and the 88-gene P3F-like expression signature, with mean expression
for the P3F-like tumors (red bar) 2.9-fold higher than in P7F-like tumors (P
0.0001). The expression of each gene in each sample was normalized in the
pseudo-colored heatmap by the number of standard deviations above (red)
and below (blue) the median expression value (black) across all samples.
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ogy). Here, we extracted the spindle/botryoid tumors
from the embryonal designation, hypothesizing that these
tumors that are typically characterized as displaying well-
differentiated histology (ie, spindle cell and botryoid),
would differ in their expression patterns when compared
with those considered to be of poorly differentiated his-
tology (ie, P-F-negative ARMS and UDS/NRSTS). Cluster
membership for P-F-negative tumors was determined as
described above for P-F RMS. Reiterative k-means clus-
tering under cross-validation identified 333 genes found
to participate in cluster centroid generation in at least
50% of the metaclustering runs (data not shown). Three
main clusters of tumors were evident (Supplemental Fig-
ure S1B available at http://ajp.amjpathol.org) and these
were used to determine gene selection for a second
round of metaclustering. The results, depicted in Figure
3, were generated using two-way hierarchical clustering
to derive a dendrogram (A) and expression matrix (B)
showing the clustering of the P-F-negative tumors based
on expression of a set of 387 genes (Supplemental Table
S6 available at http://ajp.amjpathol.org). Two main gene
clusters and three sample clusters were resolved by
hierarchical clustering. One cluster of tumors (n  29)
includes 5 P-F-negative alveolar, 4 spindle/botryoid, and
20 embryonal histology tumors and show increased ex-
pression of a group of 176 genes. Overrepresentation
analysis of this cluster demonstrates enrichment of GO
terms such as BP muscle contraction, CC muscle fiber,
and MF structural constituent of muscle, and genes
localized to chromosome 1q (Supplemental Table S7
available at http://ajp.amjpathol.org). These tumors
thus expressed a muscle differentiation gene signature,
including the highest levels of MYOD1 and MYOG (Sup-
plemental Figure S2 available at http://ajp.amjpathol.org)
among the total tumor cohort, both of which are well-
established markers of rhabdomyogenesis.20 This group
was henceforth classified as well-differentiated RMS (WD
RMS).
A second cluster of genes (n  203) is expressed by
both the WD RMS and a second tumor cluster (n  44),
which included 9 alveolar, 4 spindle cell, 1 UDS/NRSTS,
and 30 embryonal histology tumors. Overrepresentation
analysis of this gene cluster reveals statistically signifi-
cant enrichment for genes localized to chromosome 11
(both 11p and 11q). Both the WD RMS class and samples
in the second sample cluster express this chromosome
11 gene signature, but the second sample cluster shows
decreased expression of the muscle differentiation sig-
nature. Accordingly we classified these tumors as mod-
erately differentiated RMS (MD RMS). Neither the muscle
differentiation nor the chromosome 11 gene signatures
are expressed in the third sample cluster (n  32), which
contains 20 tumors with embryonal histology, 1 botryoid
tumor, and 11 UDS/NRSTS histology tumors. A very small
group of genes (n  6, too few for overrepresentation
analysis) form a gene cluster expressed in these 20
tumors but not in the WD and MD RMS clusters. In con-
trast to our initial hypothesis, we did not find that histo-
logically well differentiated tumors (ie, spindle cell and
botryoid RMS) co-cluster nor did we observe the P-F-
negative alveolar histology tumors to co-cluster. Instead,
these tumors were distributed evenly across the WD and
MD tumor clusters. Notably, the UDS/NRSTS cluster,
which as the name implies is enriched for UDS/NRSTS
histology tumors, also contains 27% of the ERMS his-
tology tumors. Box plots of established markers of rhab-
domyogenesis, MYOD1 and myogenin, suggest that his-
tological classification does not explain the variance in
expression observed for these markers within histolog-
ical classes (Supplemental Figure S2, A and B, avail-
able at http://ajp.amjpathol.org). In contrast, the molec-
ular classes identified display decreased variance in
expression for each marker, suggesting that the degree
of rhabdomyogenesis is a key component of the overall
phenotype of these tumors, information that is not captured
by the current ICR classification but has been suggested
previously in alternate classification schemes.5,18,22,40,41
Figure 3. Semi-supervised expression profiling of P-F-negative tumors.
PAX-FKHR fusion-negative tumors (n  105) were subjected to two consec-
utive rounds of cross-validated metaclustering. The results of the second
round of metaclustering are presented in the hierarchical clustering dendro-
gram (A) and expression matrix (B). Three main sample clusters are resolved,
two clusters on the left branch comprised of an assortment of histological
subtypes of P-F-negative RMS and one cluster on the right branch contained
most of the NRSTS tumors but also27% of all ERMS tumors. See Figure 1 for
tumor sample color legend. The expression matrix depicts the 176-gene
muscle differentiation expression signature, highly expressed in well-differ-
entiated WD RMS (blue bar), with mean expression levels 3- and 12-fold
greater than in moderately-differentiated MD RMS (green bar) and the UDS/
NRSTS (brown bar) tumor classes, respectively (P  0.0001). The 203-gene
chromosome 11 expression signature is expressed at similar levels in WD and
MD RMS classes, both more than threefold greater than UDS/NRSTS tumors
(P  0.0001). A small gene cluster of just six genes is expressed at increased
levels in the UDS/NRSTS class (arrow). The expression of each gene in each
sample was normalized in the pseudo-colored heatmap by the number of
standard deviations above (red) and below (blue) the median expression
value (black) across all samples.
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LOH Analysis of RMS
High-density single nucleotide polymorphism (SNP) ar-
rays have been used for high-throughput studies to de-
tect allelic imbalance by analysis of the distribution of
polymorphic sites.42–44 Using SNP oligonucleotide ar-
rays detecting 11,555 genome-wide SNPs we performed
LOH analysis for a subset of 73 tumors (of which 63
samples had corresponding gene expression data) (Sup-
plemental Table S8 available at http://ajp.amjpathol.org).
Chromosomal regions were divided into 15-Mb regions
(for a total of 182 regions excluding sex chromosomes)
and the probability of LOH was calculated for each re-
gion (for each sample) as well as the fractional allelic loss
(FAL), a measure of the overall allelic imbalance for each
sample (see Materials and Methods). Nearly all tumors
(94%) had at least one 15-Mb region with LOH but the
overall degree of LOH, represented by the FAL, differed
greatly between the histological groups (Figure 4A).
ERMS histology tumors (including the spindle/botryoid
designation) had higher levels of FAL (approximately
twofold greater) than ARMS (P  0.005). Interestingly, as
a separate entity, P-F-negative ARMS (n  4) had mean
FAL (0.16  0.06) more than twofold greater than P-F
RMS (0.07  0.02, P  0.02), but similar to that of other
P-F-negative embryonal (0.14  0.02) and spindle/botry-
oid (0.18  0.05) histology tumors (P  0.8) (Figure 4B).
Tumors with UDS/NRSTS histology had mean FAL levels
similar to the P-F RMS (0.05  0.02) and nearly threefold
lower than ERMS tumors. Twelve tumors that were clas-
sified by expression profiling in the previous section as
UDS/NRSTS had associated SNP data. Most of these
tumors were by central review of ERMS histology (n 
10), but the mean FAL in this molecular class (0.07 
0.01) was significantly lower than the mean FAL observed
in the WD (0.14  0.04) and MD (0.17  0.03) RMS
classes (Figure 4C). Intriguingly, this subset of ERMS
histology tumors (that co-clustered with UDS/NRSTS his-
tology tumors) did not have significantly different mean
FAL observed in the UDS/NRSTS histology tumors (n 
5). The overall levels of allelic imbalance (ie, FAL) ob-
served in this cohort of RMS tumors are nearly identical to
those reported by Visser and colleagues.16
We next analyzed genome-wide patterns of LOH to
compare recurrent regions of allelic imbalance in the ICR
histological and molecular subclasses. Figure 5 shows a
map of 52 genome-wide 15-Mb regions with LOH in at
least 10% of tumors. Similar to the results obtained by
others,16 the predominant regions of LOH were found
along chromosome 11, including both the long and short
arms. Nearly 70% of the tumors analyzed had at least one
region of LOH along chromosome 11 (including 55% at
11p and 41% at 11q). The proportion of ERMS (including
classical embryonal and spindle/botryoid histological
subtypes) with LOH along chromosome 11 was consid-
erably higher (at 80%) than in other histological groups
(P  0.002). Other chromosome regions that showed
frequent allelic imbalance included 8q, 10q, 10p, 6q, and
4q (Figure 5 and Supplemental Table S9 available at
http://ajp.amjpathol.org). For chromosome 11p15, 77% of
the P-F-negative RMS displayed LOH of this region (in-
cluding all four P-F-negative ARMS) compared with only
24% of P-F RMS and no UDS/NRSTS tumors (P  0.001).
For P-F RMS subclasses, we found that 46% of P3F-like
tumors displayed LOH on chromosome 4q in contrast to
only 22% of P7F-like tumors (P  0.008) (Figure 5 and
Supplemental Table S9 available at http://ajp.amjpathol.
org). Chromosome 1q LOH was observed in 50% of the
WD but only 21% of the MD P-F-negative RMS tumors
(P  0.002). Intriguingly, these regions were overrepre-
sented in the P3F-like and WD RMS muscle differentiation
gene signatures, respectively (Supplemental Tables S5
and S7 available at http://ajp.amjpathol.org). The lone
UDS/NRSTS tumor that clustered in the MD RMS class
did not show chromosome 11 LOH, although it did ex-
press the chromosome 11 gene expression signature
(Figure 5, green arrow). In the UDS/NRSTS molecular
class, only 3 of 10 embryonal histology tumors that co-
clustered with these histological UDS/NRSTS tumors (ie,
by gene expression profiling in previous section) dis-
played chromosome 11 LOH. The other seven did not
Figure 4. Genome-wide allelic imbalance of RMS and NRSTS using single
nucleotide polymorphism microarray analysis. A: Mean fractional allelic loss
for each of the three main ICR histological groups (analysis of variance, P 
0.005). B: Mean fractional allelic loss in which ARMS tumors are subdivided
by P-F fusion status and ERMS tumors by histological variants (ERMS 
classical embryonal, S/B  spindle or botryoid) (P  0.006). C: Mean
fractional allelic loss for tumors according to gene expression-based molec-
ular classes (P  0.003). Numbers in bars indicate the number of tumors
analyzed.
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and shared a sparse LOH pattern similar to histological
UDS/NRSTS tumors (Figure 5, brown arrows). A more
detailed view of the proportion of tumor samples with
chromosome 11 LOH, highlighting the two regions with
the highest overall levels of LOH, 11p15.4 and 11q22.1,
is depicted in Supplemental Figure S3 available at
http://ajp.amjpathol.org.
Kaplan-Meier Analysis of Patient Survival
Stratified Using ICR and Molecular Tumor
Classes
The importance of the differential diagnosis RMS to risk-
adapted therapy is clearly established.21 As can be seen
by Kaplan-Meier analysis for overall survival (OS), tumor
histology is a significant prognostic factor in our data set,
representative of the overall trends observed in the pre-
vious IRS-IV studies (Figure 6A).8,9 ERMS histology tu-
mors had a 5-year OS of 80%, significantly better than
either ARMS or NRSTS histology tumors, which both had
an OS of 52% (log-rank test, P  0.001). For tumors with
ARMS histology we found that the gene expression-de-
rived subclasses of ARMS tumors, which are not recog-
nized by the conventional classification, imparted addi-
tional prognostic power (Figure 6B). Superior outcome for
Figure 5. Genome-wide patterns of LOH, as determined across 15-Mb
windows in 29 ARMS, 39 ERMS, and 5 NRSTS tumors. LOH regions are
labeled at the bottom of the LOH map according to chromosome and the
region start point in Mb from the p-terminus. LOH map is color-coded in the
legend according to the probability of LOH as determined by the expected
versus observed heterozygous frequency. Samples are color-coded in legend
as in Figure 1. Brown and green arrows indicate seven ERMS tumors that
co-clustered with UDS/NRSTS and an NRSTS tumor that co-clustered with
MD RMS molecular class, respectively.
Figure 6. Kaplan-Meier overall survival estimates comparing conventional
and molecular classes. A: Patient overall survival by ICR histology-based
classification. B and C: Patient overall survival for gene expression-based
classes of P-F RMS (ARMS) and P-F-negative tumors (ERMS, ARMS, UDS/
NRSTS), respectively. Log-rank test P values in tests for homogeneity are
indicated below the curves.
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patients with P7F-like tumors (92% 5-yr OS) and poor
outcome for P3F-like ARMS (35% 5-year OS) was ob-
served (log-rank, P  0.03); however, these differences
were not independent of PCR-based translocation anal-
ysis by multivariate analysis (data not shown). The results
were less striking for P-F-negative RMS and UDS/NRSTS
histology tumors with respect to survival differences be-
tween gene expression-based subclasses of these tu-
mors (Figure 6C). The WD molecular class had the best
outcome with a 5-year OS of 87%, followed by the MD
and UDS/NRSTS molecular classes with OS of 72% and
62%, respectively (log-rank, P  0.1). Differences be-
tween the WD class and all other P-F-negative tumors (ie,
MD and UDS/NRSTS classes) were, however, statistically
significant (log-rank, P  0.05). Survival analysis of pa-
tients grouped by gene expression-based classes, there-
fore, imparts additional prognostic information not recog-
nized by the conventional ICR classification system, and
further supports the notion that within the broad histolog-
ical determination, there exist subclasses of these tumors
with distinct biological (ie, gene expression, myogenic
differentiation) and clinical characteristics.
Defining a Minimal Discriminatory Gene
Signature for RMS Tumors
We used the nearest shrunken centroids classification
algorithm32 to determine whether the consensus mo-
lecular classes observed with analysis of the expres-
sion patterns of hundreds of genes (ie, P-F RMS, P-F-
negative RMS, and UDS/NRSTS), are reliably identified
with a shrunken subset of less than 20 genes.. Such a
minimal expression signature would be more suited
than whole-genome arrays for routine clinical practice
(eg, through the use of quantitative RT-PCR or other
assays). Samples evaluated for this analysis consisted
of the 55 P-F-positive ARMS histology tumors, 93 P-F-
negative tumors (embryonal, spindle, botryoid, and al-
veolar) and 12 UDS/NRSTS histology tumors (undiffer-
entiated or other) (Figure 1). This combines the
accepted or consensus molecular genetic classifiers
(ie, P-F-positive or -negative) with the ICR histological
classification scheme, and permits closer comparison
of a putative expression-based scheme to a purely
histological classification scheme. We found a minimal
gene set of just five genes that can discriminate the
160 tumors into the three gene expression-based
classes (ie, PF-RMS, P-F-negative RMS, and UDS/
NRSTS) with an error rate of 5% estimated using leave-
one-out cross-validation (Table 2 and Supplemental
Figure S4A available at http://ajp.amjpathol.org). Rhab-
domyogenic genes such as CDH15 (encoding muscle
cadherin) and MYOG (encoding myogenin) distinguish
all RMS tumors from the UDS/NRSTS class. No individ-
ual genes were singularly correlated to the P-F-nega-
tive RMS tumor category (ie, highly expressed in P-F-
negative but not in either P-F-positive RMS or UDS/
NRSTS) but the P-F-positive tumors are distinguished
by high expression of TFAP2B (encoding transcription
factor AP-2), CNR1 (encoding cannabinoid receptor
1), and CDH3 (encoding placental P-cadherin). By
comparison, leave-one-out cross-validation using this
five-gene expression signature as predictors of the
conventional ICR-histological class (ie, ARMS, ERMS,
UDS/NRSTS) revealed an estimated error rate of 15%
(ie, actual ICR class was different from the molecular
class prediction for 24 tumors) (Supplemental Figure
S4B available at http://ajp.amjpathol.org). This high er-
ror rate is attributable to the inclusion of P-F-negative
ARMS with P-F RMS in the histological ARMS designa-
tion (red arrows, Supplemental Figure S4B available at
http://ajp.amjpathol.org). All of the P-F-negative ARMS
had class prediction probabilities consistent with the
other P-F-negative RMS (and not the P-F RMS tumors)
using this five-gene signature. This analysis further
reiterates the molecular genetic dichotomy of RMS tu-
mors (ie, based on an presence or absence of P-F
fusion gene expression) and demonstrates that highly
accurate RMS subtype distinction (ie, ARMS from
ERMS, RMS from UDS/NRSTS) is possible by analyzing
the expression patterns of a small number of putative
diagnostic genes.
TMA IHC for RMS Subtype Distinction
IHC is the most common molecular technique used by
pathologists to aid in the differential diagnosis of RMS,
NRSTS, and other small blue round cell tumors of child-
hood, primarily using antibodies to detect myogenic
markers such as MyoD and desmin.19 However, there are
currently no reliable markers to distinguish among RMS
subtypes, aside from P-F fusion gene detection by FISH
or RT-PCR. We therefore used rank-ordered gene lists
(Supplemental Table S2 available at http://ajp.amjpathol.
Table 2. Genes used by Nearest Shrunken Centroids for Cross-Validated Class Prediction
Affy ID Symbol Gene name Class Discriminator
Mean affymetrix difference
intensity
P-F RMS F- RMS* UDS/NRSTS
214451_at TFAP2B Transcription factor AP-2 beta P-F RMS 495 2 2
213436_at CNR1 Cannabinoid receptor 1 (brain) P-F RMS 673 12 14
203256_at CDH3 Cadherin 3, type 1, P-cadherin (placental) P-F RMS 162 1 1
206327_s_at CDH15 Cadherin 15, M-cadherin (myotubule) RMS versus UDS/NRSTS 256 158 16
207282_s_at MYOG Myogenin (myogenic factor 4) RMS versus UDS/NRSTS 374 106 2
*P-F negative RMS.
Note: all P values 0.00001.
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org) to evaluate candidates for potential utility as IHC
diagnostic markers for RMS. We chose those genes with
high levels of expression and high specificity based on
their statistical association with the three main molecular
classes of RMS, and further filtered them by the availabil-
ity of commercial antibodies. As observed in the nearest
shrunken centroids analysis, TFAP2 was highly ex-
pressed by P-F-positive RMS tumors with mean expres-
sion levels that were greater than 200-fold relative to all
other RMS tumors (P  0.00001, Supplemental Figure S5
available at http://ajp.amjpathol.org). For the P-F-negative
RMS tumors, the transcription factor encoding gene,
HMGA2, was identified as being up-regulated in these
tumors. Although HMGA2 expression partially over-
lapped with P-F-positive RMS, it nonetheless strongly
correlated with P-F-negative tumors, which had mean
expression levels of greater than eightfold over P-F-pos-
itive RMS (P  0.00001). Notably, there was no statistical
difference in expression among P-F-negative tumors with
alveolar versus embryonal histology (P  0.8, Supple-
mental Figure S5 available at http://ajp.amjpathol.org). We
then used RMS TMAs for high-throughput analysis of
protein levels of these markers among the different RMS
tumor types (Figure 7). TMAs containing 209 tumor and
normal sections from 64 unique ARMS and ERMS cases
(32 each) were tested in these assays, representing an
independent data set of tumors not previously analyzed
by microarray analysis. As shown in Figure 7, HMGA2
antibodies positively stain ERMS and fusion-negative
ARMS, but react poorly with PAX3-FKHR- or PAX7-FKHR-
positive ARMS. In contrast, the latter stained strongly with
antibodies to TFAP2. The IHC results validate the gene
expression data and demonstrate the utility of TFAP2 as
a P-F-positive RMS biomarker. TFAP2 immunostaining
showed a sensitivity of 90% and a specificity of 100%,
resulting in an overall predictive accuracy for P-F RMS of
96%, which is similar to results reported recently by oth-
ers.35 For HMGA2, the sensitivity, specificity, and overall
accuracy to distinguish P-F-negative RMS from P-F-pos-
itive RMS were 79%, 86%, and 82%, respectively; this is
significant because of the current lack of available bi-
omarkers for the ERMS subtype. Based on these two
novel markers, we believe that virtually all cases of P-F-
negative and P-F-positive RMS can be differentially diag-
nosed by IHC on formalin-fixed, paraffin-embedded tu-
mor sections.
Discussion
Several important conclusions emerge from our analysis
of RMS, which represents the largest gene expression
profiling study performed to date for this disease.28,36 We
find that homogeneous and reproducible subtypes of
RMS, as reflected in gene expression profiles, are at
odds with the International Classification of Rhabdomyo-
sarcoma, which is based on histological and cytological
features, alone. Our data indicate that RMS can be effec-
tively divided into two main molecular classes, similar to
previous reports that found a dichotomy between tumors
with type-specific genetic alterations (eg, recurrent trans-
locations) and tumors with complex karyotypes in adult
soft-tissue sarcomas.45,46 We define P-F RMS tumors as
those with a specific translocation (eg, PAX3-FKHR or
PAX7-FKHR), which is associated with a homogenous,
tightly clustering gene expression profile. These tumors
also show decreased allelic imbalance or genomic loss in
terms of LOH. Our results are supported by previous in
vitro experiments, in which we and others have charac-
terized PAX-FKHR expression signatures from analysis of
PAX-FKHR model systems and found them to be highly
correlated to primary P-F RMS gene expression pro-
files.31,38 The notion that PAX-FKHR expression serves to
define the ARMS subtype has been put forth by other
authors,11,47 and comparisons of P-F RMS to P-F-nega-
tive RMS on a smaller cohort of cases36 found no statis-
tically significant differences between P-F-negative
ARMS and ERMS. Here we show in a larger cohort of
RMS cases that there is little distinction between P-F-
negative ARMS and ERMS gene expression profiles, but
that these tumors are clearly distinct from P-F-positive
tumors. Thus it may be more appropriate to define tumors
both by histological appearance (alveolar, embryonal,
and the embryonal variants) and by fusion status (PF-
positive and PF-negative). In addition, we found levels of
allelic imbalance and patterns of LOH of P-F-negative
ARMS to be more consistent with ERMS than P-F RMS.
Others have similarly reported on comparative genomic
hybridization data of PAX-FKHR and P-F-negative ARMS,
Figure 7. Immunohistochemical analysis of an independent set of RMS
TMAs validates oligonucleotide microarray results and demonstrates the
utility of TFAP2 and HMGA2 in RMS diagnosis on formalin-fixed tissue.
ERMS TMA with antibodies detecting HMGA2 (left) and ARMS TMA (right)
with antibodies detecting TFAP2 are shown on the top row. Representative
serial tumor sections are shown staining for HMGA2 (left column, embry-
onal and alveolar fusion-negative) and TFAP2 (right column, PAX3-FKHR
alveolar). Insets show number of positively staining tumors out of total.
ERMS and ARMS TMA were counterstained with hematoxylin and methyl
green, respectively. Original magnifications, 200.
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in which the latter share similar chromosomal gains with
ERMS tumors but not with P-F-positive ARMS.48
The gene expression profiles of P-F RMS versus P-F-
negative RMS is dominated by neurogenesis-associated
genes. This is somewhat unexpected, given the tradi-
tional notion of RMS as arising from skeletal muscle cells.
Given the well-established role for wild-type Pax3 and
Pax7 in neurogenesis during early development,49 PAX-
FKHR fusion gene expression in RMS cells may aber-
rantly activate neurogenesis transcription normally silent
in the myogenic lineage, resulting in tumor cells with an
inherent muscle phenotype but accompanied by the ex-
pression of genes characteristic of neurogenic cell lin-
eages.31,50 In addition, we found that genes seemingly
repressed in P-F RMS (ie, with increased expression in
P-F-negative tumors) were overrepresented by genes lo-
calized to chromosome 8q. This is tightly correlated with
the observed increased incidence of 8q LOH (specifi-
cally 8q24) in P-F-negative tumors and reports by others
of copy-number change in ERMS but not ARMS, support-
ing the hypothesis that deregulation of gene expression
in chromosome 8 is a consequence of copy number
change specific to ERMS.48,51,52 We also found addi-
tional subclasses of P-F-positive RMS in which tumors
segregated on the basis of P7F-like or P3F-like gene
expression signatures. We observed that patients with
P7F-like tumors had significantly improved outcomes in
comparison to patients with P3F-like tumors (ie, 93%
versus 35%). Sorensen and colleagues,13 reported pre-
viously that PAX7-FKHR expression is correlated with
better patient outcome than PAX3-FKHR expression in
ARMS, but this only reached statistical significance for
patients with metastatic disease.53 Because of this am-
biguity, specific PAX-FKHR gene fusion status is not yet
been factored into treatment protocols. The gene expres-
sion data presented here suggests that there are in fact
distinct populations of P-F-positive tumors and that these
may not be simply correlated only to the type of fusion
variant expressed (ie, P3F-like and P7F-like molecular
classes) but additional as yet unrecognized or identified
molecular features. The P3F-like and P7F-like subclasses
are also supported by LOH data in which we found an
increased proportion of 4q LOH in the P3F-like tumors
that is also correlated to enrichment of genes localized to
4q in the P3F-like gene expression signature. It is impor-
tant to note that these molecular classes did not impart
additional prognostic information over PCR-based classes
(ie, PAX3-FKHR and PAX7-FKHR tumors) but taken to-
gether the molecular and clinical evidence suggests that
there exist ARMS subtypes (ie, PAX7-FKHR or P7F-like
tumors) with a superior prognosis.
P-F-negative RMS tumors are typically characterized
by complex karyotypes, displaying higher overall levels
of allelic imbalance, more pronounced LOH, and heter-
ogeneous gene expression profiles. Based on our find-
ings, these tumors can be distinguished from undifferen-
tiated and NRSTS histology tumors by expression of
muscle differentiation and chromosome 11 gene expres-
sion signatures, and by increased LOH of chromosome
11. UDS/NRSTS molecular class tumors do not express
muscle lineage markers, and display lower overall levels
of allelic imbalance (similar to P-F RMS) and fewer re-
gions of LOH, particularly along chromosome 11. In our
molecular classification analysis, the UDS/NRSTS desig-
nation included 25% of all embryonal histology tumors.
These embryonal tumors generally had lower levels of
FAL similar to UDS/NRSTS histology tumors, and only a
few showed LOH of chromosome 11. Although most LOH
in tumors is thought to arise sporadically, recurrent re-
gions of LOH are described in ERMS, such as that of
chromosome 11p15.5.54,55 A potential consequence of
LOH is gene dosage imbalance, in which loss of one
allele can cause overexpression from the retained allele
(dosage compensation)56 or allele-specific amplifica-
tion.42 This phenomenon may explain why several chro-
mosomal regions were overrepresented in tumor class-
specific gene expression signatures even though there
was also increased frequency of LOH in the same tumor
class. The most striking example is the enrichment of
genes localized to chromosome 11 in the chromosome
11 expression signature, coupled with the predominance
of LOH along chromosome 11 in P-F-negative RMS but
not UDS/NRSTS. Previous comparative genome hybrid-
ization studies have shown amplification of chromosome
11,48 which coupled with the high degree of LOH on
chromosome 11 observed, suggests that allele-specific
or amplification of the retained allele occurs in these
tumors. Studies with higher density SNP, copy number,
and exon-specific expression arrays are currently un-
derway to examine the genome and transcriptome at
higher resolution to better understand these intriguing
observations.
Contrary to what was expected, we did not find a
distinct expression signature for the spindle cell or bot-
ryoid ERMS variant tumors. These tumors are recognized
as highly myogenic, well differentiated tumors with supe-
rior expected outcomes for patients.57 However, on a
molecular level we could not distinguish spindle/botryoid
tumors from a subset of other P-F-negative (including
surprisingly, P-F-negative alveolar histology) RMS tu-
mors. These tumors had elevated expression of a char-
acteristic muscle differentiation gene signature and con-
sequently classified as the well differentiated WD RMS
subclass. Perhaps, a specific expression signature for
spindle or botryoid variants eluded us do to the limited
numbers available for study or alternatively, that this dif-
ferentiated molecular phenotype is one favorable prog-
nostic factor but the fact that these tumors arise in ana-
tomical locations that are more amenable to complete
surgical resection is an overriding prognostic factor.
These can be distinguished from other RMS tumors such
as the moderately differentiated, or MD RMS subclass,
which had intermediate expression levels of this signa-
ture, and the UDS/NRSTS molecular class, where this
expression signature was not detected. The WD class
also showed increased expression of genes localized to
chromosome 1q and accordingly, LOH analysis revealed
this to be a region frequently lost in the WD but not the
MD or UDS/NRSTS classes. Finally, outcome for WD RMS
patients (5-year OS 87%) maybe be somewhat better
than either the MD RMS or UDS/NRSTS classes, ap-
proaching the survival of localized embryonal disease.9
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Because the proportion of UDS/NRSTS cases in our
study is low, a definitive gene expression signature for
this subclass remains elusive. Therefore the diagnosis of
UDS/NRSTS is still a diagnosis of exclusion, as reported
in the original ICR classification study.3 Intriguingly, we
found nearly a third of embryonal histology tumors (n 
32) with expression profiles more similar to UDS/NRSTS
histology tumors. These poorly differentiated ERMS tu-
mors were found to have lower levels of FAL, fewer char-
acteristic chromosome 11 LOH events, significantly lower
expression of established rhabdomyogenic markers
such as MYOD and MYOG, and decreased overall sur-
vival than the majority of ERMS histology tumors. In IRS-IV
treatment protocols, UDS/NRSTS was included but in
current practice these tumors are excluded from COG
RMS trials, so this distinction maybe of less clinical sig-
nificance at present. Further studies should however,
revisit this issue to more fully understand the link between
the degree of myogenic differentiation in RMS tumors to
patient prognosis.40,58,59
We also identified a five-gene signature that was highly
predictive of the broader gene expression based tumor
classes, with only a small (5%) misclassification rate. The
five-gene classifier uses three genes highly expressed in
P-F RMS (TFAP2, CDH3, and CNR1) to distinguish
these tumors from P-F-negative RMS, irrespective of tu-
mor histology. Quantitative RT-PCR analysis of these
three genes could prove to be more reliable in clinical
practice than molecular genetic assays for tumor-specific
translocations because the latter can be confounded by
variant gene fusions (eg, PAX3-NCOA1 or PAX3-AFX).
Such variants are not picked up with standard PAX-FKHR
RT-PCR or FISH assays, but these tumors are predicted
to retain the overall P-F RMS expression signature.36 Two
additional genes (MYOG, CDH15) were identified that
distinguish RMS from UDS/NRSTS. MYOG is used rou-
tinely to aid in the diagnosis of RMS and has shown
relatively high specificity in a recent IHC study of a large
cohort of tumors.20 Finally, we found that antibodies di-
rected against TFAP2 and HMGA2 proteins can be
used for routine evaluation of clinical FFPE tissue sec-
tions. Analysis of an independent RMS TMA cohort (no
overlap of samples used for microarray analysis) found
that expression of TFAP2 is highly specific for P-F RMS,
as suggested previously by others.35 This is the first
report characterizing HMGA2 IHC for the distinction of
P-F-negative RMS from P-F RMS. Wachtel and col-
leagues,35 recently reported their IHC findings for EGFR
and fibrillin-2 on a large cohort of RMS tumors that show
an overall accuracy of 62% and 73%, respectively, for
distinguishing ERMS from ARMS. With these markers
fusion-negative ARMS and P-F ARMS cannot be distin-
guished from each other whereas with HMGA2, we found
an overall accuracy of 82% for distinguishing all P-F-
negative RMS (including fusion-negative ARMS) from P-F
RMS. The gene expression, SNP, and immunochemical
profiles of RMS tumors presented here and previous work
by us31 suggest that on a molecular level fusion-negative
ARMS are more similar to fusion-negative ERMS than
they are to phenotypically similar P-F RMS. Differences
between molecular classification schemes proposed by
Wachtel and colleagues,35 and our group are being in-
vestigated in follow-up studies currently underway.
In conclusion, a molecular classification of RMS
classes such as outlined here may allow better charac-
terization of molecularly distinct subgroups of RMS. A
molecular-based classification might be more relevant
toward directing subtype-specific therapeutics and is
likely more tightly linked to underlying biology, such as
chimeric gene expression and allelic imbalances, com-
pared with historically defined classes based on histol-
ogy. Perhaps, a hybrid model combining histopatholog-
ical and molecular-based class (ie, P-F expression
status) will be the most useful to clinicians and their
patients. It will be important to test these new findings in
a prospective analysis of uniformly treated RMS patients,
as is planned in future COG studies of this disease.
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